Mandate

Vinge has advised Ambea on a rights issue

Vinge has advised Ambea AB (publ) on a fully subscribed rights issue, which will provide Ambea with issue proceeds amounting to approximately SEK 1,215 million before costs.

The new shares are expected to be admitted to trading on Nasdaq Stockholm on 25 June 2019.

Ambea is the market leading private care provider in Sweden, Norway and Denmark respectively, with about 900 units and around 26,000 employees. Through the brands Nytida, Vardaga, Lära, Klara, Stendi and Altiden, Ambea provides housing, support, education and personnel for health and social care.

Ambea is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team consisted primarily of Charlotte Levin, Nils Fredrik Dehlin, Annika Nyberg Ekenberg and Marcus Gustavsson.
 

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026